Analysts’ Opinions Are Mixed on These Healthcare Stocks: Syros Pharmaceuticals (NASDAQ: SYRS) and Advaxis (NASDAQ: ADXS)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Syros Pharmaceuticals (NASDAQ: SYRS) and Advaxis (NASDAQ: ADXS).

Syros Pharmaceuticals (NASDAQ: SYRS)

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $10. The company’s shares closed yesterday at $12.47.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 8.9% and a 53.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Syros Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.

Advaxis (NASDAQ: ADXS)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Advaxis (NASDAQ: ADXS) today and set a price target of $6. The company’s shares closed yesterday at $1.95, close to its 52-week low of $1.75.

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.5% and a 35.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Advaxis is Moderate Buy and the average price target is $5.50, representing a 182.1% upside.

In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $5 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.